Affiliation:
1. Yale University Radiology and Biomedical Imaging
2. Yale University School of Medicine, Alzheimer's Disease Research Unit
3. Yale University School of Medicine, Neurology
Abstract
Abstract
Objective
Currently available literature on the relationships between cerebrospinal fluid (CSF) biomarkers and cognitive performance in frontotemporal dementia (FTD) is very limited and inconclusive. In this study, we investigated the association of cognition, as measured with Montreal Cognitive Assessment (MoCA), with CSF levels of total tau (t-tau), phosphorylated tau at threonine 181 (p-tau181), and amyloid β 1–42 (Aβ1–42) in a group of patients with FTD and Alzheimer’s disease (AD).
Methods
We conducted a retrospective cohort study with participants selected from the electronic records of patients seen at Yale New Haven Hospital’s Memory Clinic, CT, USA. We included 61 patients, 28 with FTD (mean age = 64.1) and 33 with AD (mean age = 66.8).
Results
T-tau levels negatively and significantly correlated with total MoCA scores as well as the different MoCA index scores in both the FTD (r=-0.469, p < 0.05) and AD (r=-0.545, p < 0.01) groups. There were no significant associations with MoCA scores and p-tau181 levels in patients with FTD (r=-0.224, p > 0.05), unlike patients with AD, who exhibited significant correlations (r=-0.549, p < 0.01). Also, Aβ1–42 levels were not significantly correlated with MoCA scores in either of the FTD and AD groups.
Conclusion
CSF concentrations of t-tau are inversely correlated to cognitive performance in patients with FTD and both t-tau and p-tau181 in AD. These findings provide valuable insights into the relationship between clinical cognitive performance and tau-related pathology in FTD.
Funder
National Institutes of Health
Publisher
Research Square Platform LLC